Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative laser therapy combined with adebrelimab in elderly patients with inoperable locally invasive bladder cancer
ChiCTR2600124182Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in bladder cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 8-week bladder event-free rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2600124182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124182.